ANDA 205272, held by Teva Pharmaceuticals USA. Dexmedetomidine Hydrochloride.
As of Nov 22, 2026, ANDA 205272 (Dexmedetomidine Hydrochloride), held by Teva Pharmaceuticals USA, was first approved by FDA on Nov 28, 2017, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 28, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dexmedetomidine HydrochlorideEQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) · injectable;injection | Dexmedetomidine Hydrochloride | Rx |
| Sep 9, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 28, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters